Connection

Maria Valsecchi to Neoplasm, Residual

Back to Details
This is a "connection" page, showing publications Maria Valsecchi has written about Neoplasm, Residual.
Maria Valsecchi
Connection Strength
0.213
Neoplasm, Residual
  1. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. Eur J Cancer. 2019 11; 122:61-71.
    View in: PubMed
    Score: 0.048
  2. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica. 2020 07; 105(7):1887-1894.
    View in: PubMed
    Score: 0.048
  3. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2018 04 20; 36(12):1240-1249.
    View in: PubMed
    Score: 0.043
  4. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018 01 20; 36(3):244-253.
    View in: PubMed
    Score: 0.042
  5. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia. J Clin Oncol. 2014 Nov 01; 32(31):3553-8.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.